Sweden's Mendus Clears Regulatory Path For Vididencel Registration Trial

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year. This marks a significant step forward in the development of Vididencel, a potential treatment derived from leukemia cells, aimed at leveraging the body's immune system to fight cancer. The regulatory clearance paves the way for the initiation of a registration trial, which is crucial for the vaccine's path to market approval.